Geode Capital Management
XLO icon

Geode Capital Management’s Xilio Therapeutics XLO Stock Holding History

Geode Capital Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$374K Buy
39,055
+1,858
+5% +$15.5K ﹤0.01% 3705
2026
Q1 		$313K Buy
37,197
+13,699
+58% +$112K ﹤0.01% 3757
2025
Q4 		$211K Hold
23,498
– – ﹤0.01% 3888
2025
Q3 		$277K Sell
23,498
-2,906
-11% -$29.1K ﹤0.01% 3824
2025
Q2 		$251K Sell
26,404
-669
-2% -$7.06K ﹤0.01% 3795
2025
Q1 		$275K Buy
27,073
+1,471
+6% +$18.5K ﹤0.01% 3748
2024
Q4 		$342K Buy
25,602
+1,445
+6% +$19.9K ﹤0.01% 3720
2024
Q3 		$266K Buy
24,157
+11,096
+85% +$136K ﹤0.01% 3808
2024
Q2 		$173K Buy
13,061
+7,002
+116% +$110K ﹤0.01% 3967
2024
Q1 		$91.7K Hold
6,059
– – ﹤0.01% 4186
2023
Q4 		$46.7K Hold
6,059
– – ﹤0.01% 4367
2023
Q3 		$179K Buy
6,059
+7
+0.1% +$261 ﹤0.01% 4027
2023
Q2 		$222K Hold
6,052
– – ﹤0.01% 3999
2023
Q1 		$269K Hold
6,052
– – ﹤0.01% 3906
2022
Q4 		$227K Buy
6,052
+81
+1% +$2.73K ﹤0.01% 4030
2022
Q3 		$243K Hold
5,971
– – ﹤0.01% 4092
2022
Q2 		$244K Sell
5,971
-4,151
-41% -$220K ﹤0.01% 4144
2022
Q1 		$1M Buy
10,122
+537
+6% +$85K ﹤0.01% 3621
2021
Q4 		$2.15M Buy
+9,585
New +$2.29M ﹤0.01% 3335

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management's XLO Position: Q2 2026 in Review

Geode Capital Management increased its Xilio Therapeutics (XLO) stake by 5% in Q2 2026, buying an estimated $15.5K and bringing the position to 39,055 shares worth $374K. The position accounts for ﹤0.01% of the portfolio, ranked #3705.

Geode Capital Management first reported a position in XLO in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.15M in Q4 2021. 24 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Geode Capital Management held 39,055 shares of Xilio Therapeutics worth $374K as of Q2 2026.
  • Geode Capital Management bought 1,858 Xilio Therapeutics shares in Q2 2026, an estimated $15.5K.
  • Xilio Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3705 holding.
  • Geode Capital Management first reported a position in Xilio Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Geode Capital Management's Xilio Therapeutics position peaked at $2.15M in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.